SAN DIEGO, Jan. 5, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced the appointment of internationally-renowned ophthalmologist, Richard L. Lindstrom, M.D., to the company's Board of Directors.
Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. He has been at the forefront of ophthalmology's evolutionary changes throughout his career as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon. Dr. Lindstrom is founder and an attending surgeon of Minnesota Eye Consultants, Adjunct Clinical Professor Emeritus at the University of Minnesota Department of Ophthalmology, and visiting professor at the U.C. Irvine Gavin Herbert Eye Institute. He serves as an advisor to numerous companies throughout the world. He also holds over 35 patents in ophthalmology and has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally. He has co-edited seven books, and published over 350 peer reviewed journal articles and 60 book chapters. Dr. Lindstrom serves on a number of journal editorial boards, including the Journal of Cataract and Refractive Surgery (JCRS) and Journal of Refractive Surgery (JRS), and is the Global Editor-in-Chief of Ocular Surgery News (OSN). He is Honorary Editor-in-Chief of the U.S./Chinese Journal of Ophthalmology. He serves on many company boards and is an esteemed member of many associations, including serving on the board of International Society of Refractive Surgery (ISRS) of the American Academy of Ophthalmology (AAO).
"We are privileged to welcome Dr. Lindstrom to Imprimis' Board of Directors – the list of his accomplishments is truly astounding," stated Mark L. Baum, CEO of Imprimis. "Dr. Lindstrom is a pioneer and highly-respected thought leader in the ophthalmology community and we look forward to his insights and contributions as we prepare for an exciting 2015 and beyond. His extensive clinical and leadership expertise will be invaluable as we continue to advance the commercialization of our ophthalmology and urology drug therapies."
Dr. Lindstrom stated, "I look forward to the opportunity to work with the Imprimis Board of Directors and management team in their commitment to deliver innovative medicines to physicians and patients at accessible prices. I have been impressed with the Company's accomplishments to date and as a current prescriber of Imprimis' Dropless Therapy, I can attest to its many benefits to patients and physicians alike."
Dr. Lindstrom is past President of the American Society of Cataract and Refractive Surgeons (ASCRS), the International Society of Refractive Surgery, the International Intraocular Implant Society and the International Refractive Surgery Club. Dr. Lindstrom serves on the ASCRS Executive Committee and is the Chair of the ASCRS Foundation. He is a Board member of the University of Minnesota Foundation, chairing the Ophthalmology and Visual Neurosciences Division.
Imprimis also announced that Gus Bassani has resigned his seat on the Imprimis Board of Directors. "On behalf of the Board of Directors, I would like to thank Gus for his valuable insights, leadership and many contributions as we advanced Imprimis from a research and development organization to a commercial-stage company," stated Robert J. Kammer, Imprimis' Chairman of the Board.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis' business is focused on its proprietary ophthalmology and urology drug formulations. The company's pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis expects to launch its urology business in 2015, which includes a patented formulation to address patients suffering from interstitial cystitis. For more information about Imprimis, please visit the company's corporate website at www.ImprimisPharma.com; ophthalmology business website at www.GoDropless.com; and urology business website at www.DefeatIC.com.
SAFE HARBOR
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704-4587
Media Contact
Deb Holliday
deb@pascalecommunications.com
412.877.4519
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-appoints-dr-richard-l-lindstrom-to-its-board-of-directors-300015260.html
SOURCE Imprimis Pharmaceuticals